- Home
- BLIV vs ARTV Comparison
BLIV vs ARTV Comparison
Compare BLIV & ARTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLIV
- ARTV
- Stock Information
- Founded
- BLIV 2014
- ARTV 2019
- Country
- BLIV Singapore
- ARTV United States
- Employees
- BLIV N/A
- ARTV N/A
- Industry
- BLIV
- ARTV
- Sector
- BLIV
- ARTV
- Exchange
- BLIV NYSE
- ARTV NYSE
- Market Cap
- BLIV 41.1M
- ARTV 39.0M
- IPO Year
- BLIV 2025
- ARTV 2024
- Fundamental
- Price
- BLIV $3.32
- ARTV $2.04
- Analyst Decision
- BLIV
- ARTV Strong Buy
- Analyst Count
- BLIV 0
- ARTV 8
- Target Price
- BLIV N/A
- ARTV $18.14
- AVG Volume (30 Days)
- BLIV 28.5K
- ARTV 366.6K
- Earning Date
- BLIV 01-01-0001
- ARTV 08-28-2025
- Dividend Yield
- BLIV N/A
- ARTV N/A
- EPS Growth
- BLIV N/A
- ARTV N/A
- EPS
- BLIV N/A
- ARTV N/A
- Revenue
- BLIV $1,355,200.00
- ARTV N/A
- Revenue This Year
- BLIV N/A
- ARTV N/A
- Revenue Next Year
- BLIV N/A
- ARTV N/A
- P/E Ratio
- BLIV N/A
- ARTV N/A
- Revenue Growth
- BLIV N/A
- ARTV N/A
- 52 Week Low
- BLIV $2.69
- ARTV $1.47
- 52 Week High
- BLIV $6.40
- ARTV $17.31
- Technical
- Relative Strength Index (RSI)
- BLIV N/A
- ARTV N/A
- Support Level
- BLIV N/A
- ARTV N/A
- Resistance Level
- BLIV N/A
- ARTV N/A
- Average True Range (ATR)
- BLIV 0.00
- ARTV 0.00
- MACD
- BLIV 0.00
- ARTV 0.00
- Stochastic Oscillator
- BLIV 0.00
- ARTV 0.00
About BLIV BELIVE HOLDINGS
BeLive Holdings is a holding company. The company is a technology solution provider for live commerce and shoppable short videos. The company enables its customers in interactive and immersive live and video commerce to the online businesses, and enables customers to create videos for more traffic and good shopping experiences on their platforms. The company generates revenue from the provision of BeLive White-Label Solutions and BeLive SaaS Solutions.
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).